"Veradigm's Bold AI Venture with ScienceIO: A Deep Dive"
Originally Published 1 year ago — by Forbes
Veradigm, formerly known as Allscripts, is attempting to revitalize itself by leveraging its $140 million acquisition of AI startup ScienceIO to harness its competitive advantage in healthcare data. The company aims to use ScienceIO's AI models to clean and structure decades worth of medical data, including 200 million patient records and 5 billion notes, for potential sale to pharmaceutical companies. With a focus on cardiac, metabolic, and central nervous system diseases, Veradigm hopes to achieve 10% revenue growth by 2026. Despite skepticism, the company, which owns the data rights, is optimistic about its AI-powered future and profitability, although concerns about data quality and privacy persist.